Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 07/28/25
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewsWire • 07/02/25
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionBenzinga • 07/01/25
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common StockGlobeNewsWire • 07/01/25
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules CapitalGlobeNewsWire • 06/30/25
Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYNPRNewsWire • 06/24/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Dyne Therapeutics, Inc. – DYNGlobeNewsWire • 06/23/25
Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating UpgradeSeeking Alpha • 06/18/25
Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYNBusiness Wire • 06/17/25
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C MeetingGlobeNewsWire • 06/17/25
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ETGlobeNewsWire • 06/16/25
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research CongressGlobeNewsWire • 06/05/25
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/08/25
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular DystrophyGlobeNewsWire • 04/24/25
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer AppointmentsGlobeNewsWire • 04/15/25
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial OfficerGlobeNewsWire • 03/20/25
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial OfficerGlobeNewsWire • 03/20/25
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 MonthsGlobeNewsWire • 03/16/25
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate BiomarkerSeeking Alpha • 03/13/25
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And RisksBenzinga • 03/12/25
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/27/25
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific ConferenceGlobeNewsWire • 02/14/25